| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA931: Zanubrutinib for treating chronic lymphocytic leukaemia |
|
Medicine details |
|
| Medicine name | zanubrutinib (Brukinsa®) |
| Formulation | 80 mg hard capsules |
| Reference number | 5201 |
| Indication | Treatment of adults with relapsed or refractory chronic lymphocytic leukaemia |
| Company | BeiGene |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 12/10/2023 |
| NICE guidance | TA931: Zanubrutinib for treating chronic lymphocytic leukaemia |